Oliver Sartor MD
Director of the Radiopharmaceutical Trials, Chief of the Genitourinary Cancer Malignancy Group, Mayo Clinic, Rochester, MinnesotaDr. Oliver Sartor is a medical oncologist in the Division of Medical Oncology in the Department of Oncology at the Mayo Clinic in Rochester, Minnesota. He serves as Chair of the Genitourinary Cancer Disease Group and the Director of Radiopharmaceutical Clinical Trials for the Mayo Clinic Comprehensive Cancer Center.
Dr. Sartor is an internationally recognized expert in prostate cancer. His medical practice and research have focused on prostate cancer since 1990 when he finished a medical oncology fellowship at the National Cancer Institute (NCI). He has published over 500 peer-reviewed articles, led or co-led multiple national and international clinical studies, including four phase III studies pivotal for FDA approval of drugs for advanced prostate cancer (Quadramet, Xofigo, Pluvicto, and Jevtana). He has lectured widely, and, at last count, has given invited lectures in 33 countries. He is the Medical Oncology Chair of the Genitourinary Cancer Committee of NRG, a national cancer research group.
Disclosures
- Consultant: Advanced Accelerator Applications (AAA); Astellas; AstraZeneca; Bayer; Blue Earth Diagnostics; Bavarian Nordic; Bristol Myers Squibb; Clarity Pharmaceuticals; Clovis; Constellation; Dendreon; EMD Serono; Fusion; Isotopen Technologien Muenchen; Janssen; Merck; Myovant; Myriad; Noria Therapeutics; Novartis; Noxopharm; Progenics; POINT Biopharma; Pfizer; Sanofi; Teneobio; Telix; Theragnostics
- Research funding: Advanced Accelerator Applications; Amgen; AstraZeneca; Bayer; Constellation; Endocyte; Invitae; Janssen; Lantheus; Merck; Progenics; Teneobio
Recent Contributions to PracticeUpdate:
- Abiraterone Plus Enzalutamide for Metastatic Hormone Sensitive Prostate Cancer
- Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy vs Observation in Oligometastatic Prostate Cancer
- Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes
- Second Primary Cancer Incidence and Risk Among Men Receiving Primary Radiotherapy vs Surgery for Prostate Cancer
- Enzalutamide for Metastatic Hormone-Sensitive Prostate Cancer
- SHR3680 Plus ADT for High-Volume Metastatic Hormone-Sensitive Prostate Cancer
- Updated Data on Use of LuPSMA for Metastatic Prostate Cancer
- Outcomes of Adding ADT and Pelvic Lymph Node Treatment to Prostate Bed Salvage Radiotherapy for Prostate Cancer
- ASCO 2022: Abstract Recommendations From Dr. Oliver Sartor for Prostate Cancer
- Niraparib in Combination With Abiraterone Acetate and Prednisone vs Abiraterone Acetate and Prednisone for Treatment of Metastatic Prostate Cancer